利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

2 条记录 (耗时 0.009 秒)

    Anti-cancer agent comprising an iNKT ligand and anti-PD-1 antibody or anti-PD-L1 antibody
    2.
    发明公开
    Anti-cancer agent comprising an iNKT ligand and anti-PD-1 antibody or anti-PD-L1 antibody 有权
    剂治疗癌症用的iNKT配体和抗PD-1抗体或抗PD-L1抗体

    公开(公告)号：EP2172219A1

    公开(公告)日：2010-04-07

    申请号：EP09004806.7

    申请日：2009-04-01

    申请人： SNU R&DB Foundation

    发明人： Kang, Chang Yuil ,  Chang, Woo Sung ,  Kim, Ji Yeon

    IPC分类号： A61K39/395 ,  A61P35/00 ,  A61K31/70 ,  C07K16/28

    CPC分类号： C07K16/2818 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2827 ,  C07K2317/76 ,  A61K2300/00

    摘要： Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1/PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer.

    摘要翻译： 配体本发明提供一种抗癌剂，其包含抗PD-1抗体或抗PD-L1抗体作为活性成分的，功能扭转哪个无反应性已经与在细胞的iNKT被诱导通过施用iNKT细胞的无反应性。 抗PD-1或抗PD-L1抗体阻断PD-1 / PD-L1介导的信号传导途径，不仅防止了的iNKT细胞配体诱导的iNKT细胞无反应性，因此而逆转已经无能的iNKT的无反应 细胞产生细胞因子。 此外，抗-PD-1或抗PD-L1抗体确保iNKT细胞的强效的抗肿瘤活性通过在转移结节在体内B16F10黑色素瘤转移模型的数量一个显著减少作为实例阐述。 共同地，抗癌药可以用于治疗癌症，特别是转移性癌症是非常有用的。